Standard Registration Procedure for Medicinal Products in Azerbaijan
The Standard Registration Procedure remains the primary pathway for obtaining marketing authorization for medicinal products in Azerbaijan. This procedure is applicable to innovative medicines, generics, biosimilars, and other pharmaceutical products that do not qualify for the Recognition or Orphan Procedure.
The registration process is administered by the Ministry of Health through the Center of Analytics and Expertise (CAE), which conducts a comprehensive scientific review of the submitted dossier.
Registration Process
The standard registration pathway typically consists of the following stages:
Dossier Preparation and Submission
Applicants submit a complete registration dossier in Common Technical Document (CTD) format. The dossier includes administrative, quality, non-clinical, and clinical documentation demonstrating the safety, efficacy, and quality of the medicinal product.
The CTD structure typically consists of:
Module 1 – Regional and administrative information
Module 2 – CTD summaries and overviews
Module 3 – Quality documentation (CMC)
Module 4 – Non-clinical study reports
Module 5 – Clinical study reports
A well-prepared CTD dossier significantly reduces review timelines and minimizes regulatory deficiencies during the assessment process.
Scientific Evaluation
Experts from the CAE assess:
Pharmaceutical quality and manufacturing compliance
Good Manufacturing Practice (GMP) status
Non-clinical data
Clinical efficacy and safety
Risk-benefit profile
Product labeling and prescribing information
Pharmacovigilance and risk management documentation, where applicable
Additional information or clarification requests may be issued during the review process.
Regulatory Decision
Upon successful completion of the assessment, the Ministry of Health grants a Marketing Authorization and the product is included in the State Register of Medicinal Products.
Following registration, the product must undergo a separate pricing review conducted by the Tariff Council. This stage typically requires 1–2 months.
Timelines
Registration review: approximately 8–12 months
Price approval: approximately 1–2 months
Total market access timeline: approximately 10–14 months
Validity of Registration
Marketing Authorizations issued through the standard registration procedure are valid for five years. Renewal applications must be submitted before expiration to ensure uninterrupted market presence.
Market Launch
Following registration and price approval, pharmaceutical companies may immediately launch their products on the private market. Future inclusion in public reimbursement programs may be considered based on healthcare priorities, budget impact, and clinical value.
The Standard Registration Procedure is particularly suitable for products that are not yet eligible for recognition or require a full local regulatory assessment.
How Nexa Pharm Supports Registration Projects
Nexa Pharm provides end-to-end regulatory support throughout the entire registration process. Our services include:
Regulatory strategy development
Gap analysis of existing registration dossiers
CTD dossier compilation and adaptation
Preparation and review of documentation
Submission management and regulatory correspondence
Deficiency response preparation
Artwork and labeling review
Pricing submission and approval support
Lifecycle management, variations, renewals, and transfers of marketing authorizations
Unlike traditional local agents, Nexa Pharm operates according to international pharmaceutical industry standards and project management practices used by leading multinational pharmaceutical companies.
Our team has experience supporting innovative medicines, orphan drugs, specialty products, and complex regulatory projects, providing pharmaceutical companies with a level of regulatory expertise typically expected from large international regulatory affairs organizations.
Whether you are a global pharmaceutical company, a specialty biotech, or an emerging healthcare innovator, Nexa Pharm serves as your local regulatory and market access partner in Azerbaijan.